Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509).
Phase of Trial: Phase II
Latest Information Update: 28 May 2013
At a glance
- Drugs Trastuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 28 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 01 Sep 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 01 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.